48 results
DEF 14A
MREO
Mereo Biopharma Group Plc
24 Apr 24
Definitive proxy
7:30am
the results of such assessment to the board; and
developing and recommending to the Board rules governing the board, reviewing and reassessing the adequacy
10-K
2023 FY
MREO
Mereo Biopharma Group Plc
27 Mar 24
Annual report
5:20pm
assessment as a key secondary endpoint, which, if successful, is expected to support submissions for full regulatory approval in the U.S. Inclusion … trials begin. The FDA must send a non-compliance letter to any sponsor that fails to submit the required assessment, keep a deferral current or fails
10-K
2023 FY
EX-10.30
MREO
Mereo Biopharma Group Plc
27 Mar 24
Annual report
5:20pm
with or statement from the FDA on a Special Protocol Assessment or equivalent, or (ii) other guidance or minutes issued by the FDA, or (iii
8-K
EX-99.1
MREO
Mereo Biopharma Group Plc
27 Mar 24
Mereo BioPharma Reports Full Year 2023 Financial Results and Provides Corporate Update
4:08pm
Outcome Assessment (DCOA) of the FDA throughout 2023, the Company has aligned on a Phase 3 study design using a patient-reported outcome (PRO) tool … , the St. George’s Respiratory Questionnaire (SGRQ) Total Score, as the primary efficacy endpoint, with a functional assessment as a key secondary endpoint
S-8
EX-4.3
MREO
Mereo Biopharma Group Plc
23 Jan 24
Registration of securities for employees
4:16pm
the Company, its affiliates, the Board, nor the Plan Administrator will have any obligation to take any action to prevent the assessment of any excise tax
8-K
EX-99.1
lkhlu1ymqp j26a
8 Jan 24
Mereo BioPharma Provides Update on Pipeline Progress and Corporate Developments
7:08am
6-K
EX-99.1
11g09
23 Oct 23
Mereo BioPharma Reports on Recent Program Developments and Provides Financial Update
4:08pm
6-K
EX-99.2
hqn8feycf sjlklyc
21 Oct 22
Mereo BioPharma Files Shareholder Circular for Upcoming General Meeting
7:06am
6-K
EX-99.1
kun3fx0ixqfg8sdnig
12 Sep 22
Data support further evaluation of PVR, CD226, and TIGIT as potential biomarkers of enrichment for etigilimab plus anti-PD1 therapy
8:17am
6-K
EX-99.1
habafnqd
31 Aug 22
Letter Reiterates Mereo’s Updated Strategic Plan to Maximize Value for All Shareholders and Corrects Rubric’s Assumptions
7:57am
6-K
a9upjtmgdrxlb6z6m
9 May 22
Current report (foreign)
8:06am
6-K
EX-99.1
jptauau9b8mle4mnp0
9 May 22
Current report (foreign)
8:06am
6-K
EX-99.1
lnvzb8uhl74
22 Dec 21
Alvelestat reported safe and well-tolerated in patients with COVID-19
7:45am
F-3
EX-1.2
554tc46t0l lhn
5 Aug 21
Shelf registration (foreign)
4:33pm
6-K
EX-99.1
3tafl840 zhwf
30 Apr 21
Mereo BioPharma and Cancer Focus Fund Announce Partnership for Phase 1b/2 Study of Etigilimab in Clear Cell Ovarian Cancer
4:05pm
6-K
EX-1.1
yeu4xq1fxd guvoo67e
10 Feb 21
Mereo BioPharma Group plc Announces Proposed Public Offering of American Depositary Shares
5:23pm